We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current TRDA market cap is 400.19M. The company's latest EPS is USD -0.1990 and P/E is -59.85.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Revenue | 0 | 0 | 25.26M | 18.17M | 43.74M |
| Operating Income | -25.94M | -25.58M | -5.78M | -16.3M | 14.01M |
| Net Income | -25.14M | -24.63M | -6.67M | -25.93M | 35.46M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 129.01M |
| Operating Income | -51.13M | -97.25M | -3.16M |
| Net Income | -51.16M | -94.62M | -6.69M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Assets | 274.46M | 252.06M | 475.57M | 493.98M | 485.03M |
| Total Liabilities | 41.24M | 39.5M | 245.96M | 287.08M | 238.37M |
| Total Equity | 233.22M | 212.55M | 229.61M | 206.91M | 246.66M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 305.83M | 252.06M | 469.19M |
| Total Liabilities | 7.12M | 39.5M | 226.83M |
| Total Equity | 298.72M | 212.55M | 242.36M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Operating | -66.48M | -93.79M | 203.4M | 168.31M | 143.82M |
| Investing | -167.44M | -148.65M | -40.44M | -153.7M | -157.44M |
| Financing | 121k | 479k | 19.54M | 19.98M | 20.35M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Operating | -50.86M | -93.79M | 139.8M |
| Investing | -4.58M | -148.65M | -138.4M |
| Financing | 307.46M | 479k | 21.04M |
| Market Cap | 400.19M |
| Price to Earnings Ratio | -59.85 |
| Price to Sales Ratio | 3.1 |
| Price to Cash Ratio | 5.92 |
| Price to Book Ratio | 1.65 |
| Dividend Yield | - |
| Shares Outstanding | 33.6M |
| Average Volume (1 week) | 80.19k |
| Average Volume (1 Month) | 77.48k |
| 52 Week Change | -23.31% |
| 52 Week High | 18.44 |
| 52 Week Low | 10.62 |
| Spread (Intraday) | 7.74 (40.89%) |
| Company Name | Entrada Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.entradatx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
